Scienture Inc.

Prioritizing Patients. Improving Outcomes.

A Branded Specialty Pharmaceutical Company

Scienture Inc

Focusing on the unmet medical needs of patients through innovative pharmaceutical products

Scienture Inc. is a NY based pharmaceutical research company. We are a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments

Our Mission

Our mission is to identify and develop innovative technology-based product concepts to create a portfolio of value-added specialty pipeline. The targeted portfolio will consist of short term and long-term opportunities with efficient development, regulatory, and commercial pathways.

Our History

Scienture was founded by Shankar Hariharan, Ph.D., with the core purpose of using technology based concepts to design and develop novel branded drug products. During the course of his long career in the pharmaceutical industry he has successfully championed many differentiated approaches to drug development with the ultimate goal of bringing products to the market that significantly improve the standard of care, while providing broad access to patients. Our Leadership team, BOD and SAB consists of some of the most renowned names in the industry with proven experience across several facets of the business.

Scienture News

October 2021

*Hauppauge, NY, October 10th, 2021. *Scienture Inc, a specialty pharmaceutical company based in Long Island NY, today announced a positive Pre-IND response from the FDA on SCN-102, their lead 505(b)(2) NDA program. SCN-102 is an oral liquid for cardiovascular use and is in advanced stages of development. Scienture had sought a Pre-IND meeting with FDA to discuss the development program and submitted a briefing book with questions pertaining to clinical, pre-clinical, safety and CMC development plan.

“Feedback on the SCN-102 development program with the FDA is a critical step for Scienture to bring this product to market to fulfill an unmet need for patients. We are happy with the FDA feedback as it provides a clear development path forward. We will continue to work with the agency to ensure that all the regulatory requirements are fulfilled for a successful NDA submission and approval”, remarked Shankar Hariharan, Founder, President and CEO of Scienture.

About Scienture

Scienture Inc. is a NY based branded, specialty pharmaceutical company. We are a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments. Learn more at http://www.scienture.com/

*Hauppauge, NY, October 11th, 2021. *Scienture Inc, a specialty pharmaceutical company based in Long Island NY, announced a positive Pre-IND response from FDA on one of their 505 (b)(2) NDA program, SCN-104. The product SCN-104 is a multi-fix-dose pen injector-based drug device combination product for convenient self-injection for CNS/Pain and is in advanced stages of development. Scienture had sought a pre-IND meeting with the agency and had previously submitted a briefing book with questions pertaining to clinical, pre-clinical, safety, CMC development plan.

“With SCN-104 being a drug-device combination delivering multiple doses, it was important for Scienture to get an agreement on the clinical and device development program with the agency. We are happy with the FDA feedback as it helps us develop a clear strategy going forward. We will continue to work with the agency to ensure that all the regulatory requirements are fulfilled for a successful NDA submission and approval”, remarked Shankar Hariharan, Founder, President and CEO of Scienture.

About Scienture

Scienture Inc. is a NY based branded, specialty pharmaceutical company. We are a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments. Learn more at http://www.scienture.com

Feb 2021

Hauppauge, NY, February 1st, 2021.Shankar Hariharan, President and CEO of Scienture, announced the addition of two new Directors Mr. Arun Agarwal and Narasimhan Mani, PhD, MBA, to company’s Board.

Mr. Arun Agarwal is a former Wall Street healthcare investment banker whose clients included some of the largest healthcare entities in the country. Formed in 2002, White Lotus Group, a real estate development firm, continues to facilitate a variety of real estate and healthcare projects totaling over $1.5 billion. Arun is a 1998 graduate from the Wharton School of Finance at the University of Pennsylvania, where he was awarded the Wharton Award for Academic Achievement. He also serves on the Boards of TinkRworks, NanoThernastics, Greater Omaha YMCA, HELP Foundation and Bemis Contemporary Arts.

Narasimhan Mani, PhD, MBA, is a proven leader with over 22 years of experience in both the scientific and business areas of the pharmaceutical industry. He is currently the CEO of Xiromed, a fast growing generic and specialty product company. His experience over the years includes multifunctional leadership roles, in branded and generic product segments, across product development, manufacturing operations, portfolio management, business development, M&A and Sales & Marketing. He held leadership positions at Elan Pharmaceuticals, Forest Laboratories, Par Pharmaceuticals, Johnson & Johnson, and Amneal Pharmaceuticals. Dr. Mani received his PhD in Pharmaceutics, from the University of Georgia, Athens and MBA in Finance and Marketing, from Columbia Business School, New York, NY.

Dr. Hariharan, who is also the chairman of the Board commented, “I am pleased to welcome Arun Agarwal and Narasimhan Mani to the Board of Directors. Their addition will be a major boost to Scienture’s growth prospects and outreach in the future.” This is the first expansion to the Board since it was formed a year ago. Sandeep Gupta, PhD, Founder and CEO of Asana Biosciences and Polireddy Dondeti, PhD, President and CEO of Saptalis Pharmaceuticals, also serve on Scienture’s Board currently.

About Scienture

Scienture Inc. is a NY based branded, specialty pharmaceutical company. We are a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments. Learn more at https://www.scienture.com/.

Jan 2021

Hauppauge, NY, January 29th, 2021. Scienture Inc, a New York based branded pharmaceutical company, today announced that Lawrence Olanoff, MD, PhD has joined the company’s Scientific Advisory Board. Dr. Olanoff is an adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina. From 2006-2010, he served as President and Chief Operating Officer for Forest Laboratories, Inc. From 2005 to 2006, Dr. Olanoff was CEO of Celsion Corporation. Prior to 2005, he served as Executive VP of Research and Development and Chief Scientific Officer of Forest, and held senior clinical research roles at Sandoz Pharmaceutical Corporation and the Upjohn Company. During his pharmaceutical development career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas. He is Chairman of the board of directors of Mitochondria in Motion, and serves as a member of the Board of Ironwood Pharmaceuticals and Ichnos Sciences, as well as several non-profit organizations. Dr. Olanoff also held past directorships on the boards of Forest Laboratories, Axovant Sciences Ltd. and the Celsion Corporation. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University, was an internal medicine resident and clinical pharmacology fellow at the Medical University of SC and is the author of some 40 scientific publications on topics including controlled drug delivery, pharmacokinetics, drug metabolism and clinical toxicology.

“We are extremely delighted and privileged to have Dr. Olanoff on the Scientific Advisory Board. He brings in a broad perspective on entire pharmaceutical development with his experience in the industry and academia and perfectly augments our two other SAB members Suneel Gupta, PhD and Wantanee Phuapradit, PhD. Having worked with Dr. Olanoff in the past, I know the depth of his commitment to helping the patients and serving unmet medical needs”, remarked Shankar Hariharan, Founder, President and CEO of Scienture.

About Scienture

Scienture Inc. is a NY based branded, specialty pharmaceutical company. We are a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments. Learn more at http://www.scienture.com/

Oct 2020

Hauppauge, NY, October 26th, 2020. Scienture Inc, a New York based branded pharmaceutical company, today announced that it completed its first round Series Seed capital raise of $6 million. The company, founded in July 2019, is in active development of a differentiated pipeline of specialty products which bring significant enhancement and transformation to the current standard of care. The products are driven by unique, cutting edge drug delivery technology concepts, inclusive of drug-device combinations. The predominant focus is on indications in the CNS space and additionally in a few other selected therapeutic areas.

“The completion of the Series Seed capital raise is an important first step for Scienture in its vision to bring value added specialty products to the market. We thank the support of all our investors in this funding round. Along with them and our leadership team at Scienture, we are deeply committed to serving unmet medical needs by employing high technology solutions in the drug delivery arena. Our goal is to provide affordable and efficient access to high value products with enhanced clinical outcomes to patients, caregivers and the healthcare system. We are excited and look forward to continuing the rapid progress we have made on each of our development programs”, commented Shankar Hariharan, Founder, President and CEO.

About Scienture

Scienture Inc. is a NY based branded, specialty pharmaceutical company. We are a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments. Learn more at http://www.scienture.com/ 

Jan 2020

 Product development activities started and underway with our strategic development partners.

Nov 2019

Initiation of IP application process for our new and novel product concepts.

Oct 2019

Scienture establishes its corporate offices in Hauppauge, NY.